Regeneron (REGN) Announces $3 Billion Share Repurchase Program

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that its Board of Directors authorized a share repurchase program of up to $3 billion of the Company's outstanding common stock.

"With the strength of our balance sheet and our business, we see this as an opportunity to continue to invest in Regeneron," said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron. "This share repurchase program is part of our broader capital allocation strategy to maximize shareholder value for years to come."

Repurchases may be made from time to time at management's discretion through a variety of methods, such as open-market transactions (including pre-set trading plans), privately negotiated transactions, accelerated share repurchases, and other transactions in accordance with applicable securities laws. The program has no time limit and can be discontinued at any time. No shares have been repurchased under the program to date. There can be no assurance as to the timing or number of shares of any repurchases. As of November 12, 2021, $1.8 million remained available for share repurchases under the prior $1.5 billion share repurchase program authorized in January 2021.

You May Also Be Interested In

• Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
• Havas repurchases 5,000 shares under €50M buyback program
• Genius Group buys back 6M shares, removes 27% of public float